Seung Min Yang

Dr. Seung Min Yang has served as a board member of Verseau since March 2021. He is the head of drug discovery research at Dong-A ST, a leading pharmaceutical company in Korea, making strategic plans for all research projects of the institute and directing alliances and collaborations with external organizations to facilitate open innovation.

After he joined Dong-A as a senior scientist and a leader of research projects in 2012, he helped set up various biochemical, biophysical, and cellular assays to develop pre-clinical candidate compounds and implemented a fragment-based drug discovery system for hit finding. While working as head of the translational chemistry team later in 2016, he made a contribution to out-licensing MERTK inhibitors, investigational immuno-oncology drug candidates, to AbbVie for $525 million.

Presently, he also serves as a board member of the Korea Drug Research Association, which is a prestigious non-profit organization of over 340 members including drug developing companies, academic institutes, and funded research institutes in Korea.

He received his B.S. and M.S. in chemistry from Seoul National University, and Ph.D. in chemistry from Yale University, where he studied DNA solution structure using kinetics combined with Monte Carlo simulation.

As a post-doc and research scientist at Albert Einstein College of Medicine, he worked on epigenetic events linked to H1 linker histones, publishing several papers in top-tier journals.